By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PhaseBio Pharmaceuticals, Inc. 

4020 Aerial Center Parkway
Suite 101
Morrisville  North Carolina  27560  U.S.A.
Phone: 919-535-8861 Fax: 919-535-8867


Start Up

Company News
PhaseBio Announces Promising Pre-Clinical Results For PB1046 In Models Of Duchenne Muscular Dystrophy 4/22/2015 7:50:43 AM
AstraZeneca PLC (AZN)-Backed PhaseBio Locks in $40 Million 3/12/2015 5:56:29 AM
PhaseBio Pharmaceuticals, Inc. Announces Expansion Of Leadership Team 3/3/2015 7:48:08 AM
PhaseBio Pharmaceuticals, Inc. Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases 6/18/2013 9:30:58 AM
PhaseBio Pharmaceuticals, Inc. Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes 6/4/2013 10:16:42 AM
PhaseBio Pharmaceuticals, Inc. to Present at the Jefferies and Co. 2013 Global Healthcare Conference 5/29/2013 11:08:58 AM
PhaseBio Pharmaceuticals, Inc. Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as Chief Business Officer 12/4/2012 10:50:15 AM
PhaseBio Pharmaceuticals, Inc. Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate Use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes 8/21/2012 9:54:55 AM
PhaseBio Pharmaceuticals, Inc. Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing for Advancement of Metabolic and Cardiovascular Product Portfolio 6/5/2012 7:34:43 AM
PhaseBio Pharmaceuticals, Inc. Launches Clinical Program to Evaluate Novel VPAC2 Agonist for Cardiovascular Disease 2/22/2012 6:34:11 AM